Iterum Therapeutics plc
ITRMF
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue
N/A
Net Income (TTM)
-$27M
▲ +35.4% YoY
Op. Margin
–
ROIC
-71.23%
▲ +76.7pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$20M
▲ +32.0% YoY
Op. Cash Flow (TTM)
-$20M
▲ +31.9% YoY
Net Debt
$9M
Cash & Equiv.
$11M
Continue Research
Peers
Pharmaceutical Preparations · Pick stocks to compare with ITRMF
Iterum Therapeutics (ITRMF) in three numbers
Questions about Iterum Therapeutics
Is Iterum Therapeutics a high-quality business?
Iterum Therapeutics scores 0 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 4 checks computed from SEC filings. Its best check is share count change at 7766.0%. The Quality tab shows every check against its target.
Does Iterum Therapeutics (ITRMF) pay a dividend?
No. Iterum Therapeutics (ITRMF) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: 10-Q filed 14 Nov 2025 (period ending 30 Sept 2025), SEC. Price: last close 19 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong? Check it in ITRMF's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing ITRMF
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.